Cenicriviroc (CVC), a dual antagonist of CCR2 and CCR5, ameliorates hepatic inflammation in NASH mice models by reducing the recruitment of CCR2+ monocyte in the liver. Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.